
The FDA granted an orphan drug designation to AVA6000 for the treatment of patients with soft tissue sarcoma.

The FDA granted an orphan drug designation to AVA6000 for the treatment of patients with soft tissue sarcoma.

AMB-05X has been granted fast track designation for the treatment of patients with tenosynovial giant cell tumor of the knee by the FDA.

The “Every Step of the Way” campaign TV spot from Florida Cancer Specialists & Research Institute, LLC received a prestigious Platinum Hermes Award in the annual 2022 Hermes Creative Awards.

Press Release
Florida Cancer Specialists & Research Institute celebrated the addition of genomic testing capabilities at its Next Generation Sequencing laboratory in Fort Myers last week with a ribbon cutting ceremony.

Findings from the phase 3 ORIENT-31 study shows improved progression-free survival with sintilimab with or without bevacizumab biosimilar injection and chemotherapy in EGFR-mutated non-squamous non-small cell lung-cancer.

The phase 2 MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone demonstrates the promise of minimal residual disease surveillance in newly diagnosed multiple myeloma with 0 or 1 high-risk cytogenetic abnormalities

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Mark Yarchoan, MD, discusses the current hepatocellular carcinoma space as well as 3 late breaking abstracts that will be presented at the 2022 ESMO Congress.

Pegfilgrastim-fpgk has been approved by the FDA for patients with febrile neutropenia following data which revealed it to have a high degree of similarity with its reference product.

In an interview with Targeted Oncology, Melina Elpi Marmarelis, MD, further discussed the findings revealed from the LACP cohort of the CHRYSALIS-2 study in non–small cell lung cancer.

David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

A patient enrolled in the phase 1 NADOM trial of darovasertib alone in non-metastatic uveal melanoma shows early signs of clinical efficacy.

Sacituzumab govitecan demonstrated promising progression-free survival efficacy in patients with HR+/HER2-low and IHC0 status metastatic breast cancer, showing its potential as a future treatment option.

A cohort of a clinical trial of the experimental agent STP705 successfully treated patients with cutaneous basal cell carcinomas, offering an alternative to surgery or other skin cancer treatment.

In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.

David Hong, MD, explains why larotrectinib may be chosen over other TRK inhibitors for the treatment of NTRK fusion-positive lung cancer.

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

The FDA has approved durvalumab for the treatment of patients with locally advanced or metastatic biliary tract cancer.

Treatment with AST-301 will be explored in patients with HER2-low breast cancer in the phase 2 Cornerstone-011 study.

Florida Cancer Specialists & Research Institute welcomes Board-certified hematologist/oncologist Shivtaj Mann, DO to the statewide practice. He is providing care to patients at the FCS Fort Myers Cancer Center, 8260 Gladiolus Drive, Fort Myers, FL 33908.

Press Release
Florida Cancer Specialists & Research Institute, LLC held a ribbon-cutting ceremony on August 18, 2022 to celebrate the opening of its newest clinical site in Pasco County.

Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.

Enrollment has begun for a phase 2 study of a polarized dendritic cell vaccine plus interferon alpha-2b, rintatolimod, and celecoxib in melanoma with PD1/PD-L1-resistance.

The PARP inhibitor rucaparib was shown to improve progression-free survival in a cohort of the ATLANTIS study platform for metastatic urothelial carcinoma.

The use of immune checkpoint inhibitors in anaplastic thyroid cancer shows a similar toxicity profile to that seen in PD-1 and PD-L1 targeting therapies.

The targeted alpha therapy, FPI-1966, has been dosed for the first time in a phase 1/2 study of patients with advanced solid tumors that express FGFR3.

Data from the phase 2 CADENZA trial revealed front-line pivekimab sunirine to demonstrate clinical activity in patients with blastic plasmacytoid dendritic cell neoplasm.

Here is a look back at the FDA happenings from the month of August 2022.

The CoMMpass genomic data set of patients with multiple myeloma was utilized by investigators, contributing to 19 abstracts reported at the International Myeloma Society.